<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02197572</url>
  </required_header>
  <id_info>
    <org_study_id>C31002</org_study_id>
    <secondary_id>U1111-1156-4099</secondary_id>
    <nct_id>NCT02197572</nct_id>
  </id_info>
  <brief_title>Effect of MLN0128 on the QTc Interval in Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Effect of MLN0128 on the QTc Interval in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the effect of a single dose of 40 mg MLN0128 on
      the electrocardiographic QT/QTc interval in participants with advanced solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called MLN0128. MLN0128 is being tested to determine
      the effect of a single 40 mg dose on the electrocardiographic measure of the time between the
      start of the Q wave and the end of the T wave in the electrical cycle of the heart (QT)/rate
      corrected QT (QTc) interval in patients with advanced solid tumors. This study will look at
      electrocardiogram (ECG) results before and after a single dose of MLN0128.

      The study will enroll approximately 30 patients. All participants will receive a single 40 mg
      dose of MLN0128 capsules on Day 1. To avoid nausea and vomiting, participants will also be
      administered 0.25 mg palonosetron on Day 1 as an antiemetic agent. Participants may continue
      to receive MLN0128 for up to 1 year at a dose of up to 30 mg once weekly if a clinical
      benefit is being derived.

      This multi-centre trial will be conducted in the United States. The overall time to
      participate in this study is up to 14 months. Participants will make 6 visits to the clinic
      including and end of study visit 30 to 40 days after last dose of study drug for a follow-up
      assessment. Participants that continue treatment with MLN0128 will continue to make
      additional visits to the clinic once or twice every 4 weeks and the end of study visit 30 to
      40 days after last dose of study drug for a follow-up assessment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 15, 2014</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 10, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Time-Matched Baseline in Individual Baseline Corrected Rate-Corrected QT Interval (QTcI) at Cycle 1 Day 1</measure>
    <time_frame>From time-matched baseline to Day 1, Cycle 1 of a 28-day cycle predose and up to 48hours postdose</time_frame>
    <description>Holter monitors will be used to collect triplicate electrocardiogram (ECG) measurements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>From Day 1, Cycle 1 through 30 days after the last dose of study drug (up to 13 months)</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment.
Serious adverse event (SAE) means any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. Relationship of each AE to study drug will be determined by the Investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings</measure>
    <time_frame>From Day 1, Cycle 1 through 30 days after the last dose of study drug (up to 13 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Potentially Clinically Significant Vital Signs Findings</measure>
    <time_frame>From Day 1, Cycle 1 through 30 days after the last dose of study drug (up to 13 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Time-Matched Baseline in QTc with Rate-Corrected QT Interval (millisec) with Bazett Correction (QTcB) at Cycle 1 Day 1</measure>
    <time_frame>From time-matched baseline to Day 1, Cycle 1 of a 28-day cycle predose and up to 48 hours postdose</time_frame>
    <description>Holter monitors will be used to collect triplicate electrocardiogram (ECG) measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Time-Matched Baseline in QTc with Rate-Corrected QT interval (millisec) Fridericia Correction (QTcF) at Cycle 1 Day 1</measure>
    <time_frame>From time-matched baseline to Day 1, Cycle 1 of a 28-day cycle predose and up to 48 hours postdose</time_frame>
    <description>Holter monitors will be used to collect triplicate electrocardiogram (ECG) measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Time-Matched Baseline in QRS Interval at Cycle 1 Day 1</measure>
    <time_frame>From time-matched baseline to Day 1, Cycle 1 of a 28-day cycle predose and up to 48 hours postdose</time_frame>
    <description>Holter monitors will be used to collect triplicate electrocardiogram (ECG) measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Time-Matched Baseline in PR Interval at Cycle 1 Day 1</measure>
    <time_frame>From time-matched baseline to Day 1, Cycle 1 of a 28-day cycle predose and up to 48 hours postdose</time_frame>
    <description>Holter monitors will be used to collect triplicate electrocardiogram (ECG) measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Time-Matched Baseline in Heart Rate at Cycle 1 Day 1</measure>
    <time_frame>From time-matched baseline to Day 1, Cycle 1 of a 28-day cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for MLN0128</measure>
    <time_frame>Cycle 1, Day 1 predose and up to 48 hours postdose</time_frame>
    <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN0128</measure>
    <time_frame>Cycle 1, Day 1 predose and and up to 48 hours postdose</time_frame>
    <description>Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for MLN0128</measure>
    <time_frame>Cycle 1, Day 1 predose and up to 48 hours postdose</time_frame>
    <description>(AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC[0-tlqc]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN0128</measure>
    <time_frame>Cycle 1, Day 1 predose and up to 48 hours postdose</time_frame>
    <description>AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (T1/2) Pharmacokinetic Parameter for MLN0128</measure>
    <time_frame>Cycle 1, Day 1 predose and up to 48 hours postdose</time_frame>
    <description>Terminal Phase Elimination Half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>MLN0128</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLN0128 40 mg, capsules, orally, once, on Day 1, Cycle 1. MLN0128 may be continued at the discretion of the investigator at a dose of up to 30 mg, capsules, orally, once weekly (QW) until disease progression, unacceptable MLN0128-related toxicity, withdrawal of consent, or for up to 12 months (whichever occurs first).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN0128</intervention_name>
    <description>MLN0128 capsules</description>
    <arm_group_label>MLN0128</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Men or women participants 18 years or older.

          2. Must have a radiographically or clinically evaluable solid tumor Eastern Cooperative
             Oncology Group (ECOG) performance status of 0 or 1.

          3. Female participants who:

               -  Are postmenopausal for at least 1 year before the screening visit, OR

               -  Are surgically sterile, OR

               -  If they are of childbearing potential, agree to practice 2 effective methods of
                  contraception, at the same time, from the time of signing the informed consent
                  through 3 months after the last dose of study drug, OR

               -  Agree to practice true abstinence, when this is in line with the preferred and
                  usual lifestyle of the participant. (Periodic abstinence (eg, calendar,
                  ovulation, symptothermal, postovulation methods] and withdrawal are not
                  acceptable methods of contraception.)

          4. Male participants, even if surgically sterilized (ie, status postvasectomy), who:

               -  Agree to practice effective barrier contraception during the entire study
                  treatment period and through 3 months after the last dose of study drug, or

               -  Agree to practice true abstinence, when this is in line with the preferred and
                  usual lifestyle of the participant. (Periodic abstinence [eg, calendar,
                  ovulation, symptothermal, postovulation methods for the female partner] and
                  withdrawal are not acceptable methods of contraception.)

          5. Voluntary written consent must be given before performance of any study-related
             procedure not part of standard medical care, with the understanding that consent may
             be withdrawn by the participant at any time without prejudice to future medical care.

          6. Ability to swallow oral medications, willingness to perform mucositis prophylaxis, and
             suitable venous access for the study-required blood sampling.

        Exclusion Criteria

          1. Female participants who are lactating and breastfeeding or have a positive serum
             pregnancy test during the screening period.

          2. Any serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with the completion of treatment according to this protocol.

          3. Treatment with any investigational products within 14 days before the first dose of
             study drug and systemic anticancer therapy within 28 days before the first dose of
             study drug.

          4. Untreated brain metastasis or history of leptomeningeal disease or spinal cord
             compression.

          5. Tumors with involvement of the mediastinum.

          6. Failure to recover from the reversible effects of prior anticancer therapies with the
             exception of alopecia, and after-effects associated with prior tyrosine kinase
             inhibitor therapy such as hair depigmentation, hypothyroidism, and/or splinter
             hemorrhage.

          7. Systemic corticosteroid (inhalers are allowed) within 7 days before the first dose of
             study drug.

          8. Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI
             disease, or for an unknown or other reason that may alter the absorption of MLN0128.

          9. Diagnosis of diabetes mellitus; participants with a history of transient glucose
             intolerance due to corticosteroid administration may be enrolled if all other
             inclusion/exclusion criteria are met.

         10. Significant active cardiovascular or pulmonary disease at study entry

             â—¦ History of arrhythmia requiring an implantable cardiac defibrillator

         11. Clinically significant comorbidities such as uncontrolled pulmonary disease, active
             central nervous system disease, active infection, serious infection within 14 days
             before the first dose of study drug, or any other condition that could compromise
             study participation by the participant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2014</study_first_submitted>
  <study_first_submitted_qc>July 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2014</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

